Abstract: The present invention relates to the use of insoluble forms of recombinant proteins in a flow cytometric immunofluorescence assay for the detection of given antibodies.

Abstract: This invention is directed to characterizing a host system suitable for the production of functional transgenic proteins, such as anti-human IgG, for use in applications requiring Government regulatory approval. It is well known that regulatory agencies required stable, consistent master cell banks and master cell lines for the production of transgenic proteins in order to ensure sufficient material for appropriate characterization, clinical trials, and potential sales. Current plant production systems require the establishment of seed banks for this purpose. However, there are many draw backs related to such a system for the production of a continuous reliable transgenic protein source. An aspect of this invention is directed to characterizing a plant production system suitable for transgenic proteins that meet the stringent regulatory requirements.

Abstract: The use of platelet-activating factor (PAF) to increase the levels of von Willebrand factor and/or Factor VIII in blood is disclosed. The use of PAF has particular application in the treatment of von Willebrand disease and haemophilia A.

Abstract: A method of obtaining Factor VIII which comprises(a) adding heparin to freshly obtained blood plasma collected into a calcium chelating anticoagulant or collecting blood plasma by plasma pheresis using heparin and a calcium chelating anticoagulant;(b) freezing the plasma;(c) resolubilizing the plasma;(d) isolating a cryoprecipitate from the plasma;(e) resolubilizing the cryoprecipiate;(f) adding a citrate saline heparin buffer to the resolubilized cryoprecipitate;(g) incubating the buffered, resolubilized cryoprecipitate at a temperature of from about 0.degree. to about 10.degree. C. for a time in excess of about one hour, whereby Factor VIII present in the cryoprecipitate is insolubilized using heparin precipitable cold insoluble globulin and the resulting Factor VIII rich precipitate also includes cold insoluble globulin;(h) separating the Factor VIII rich precipitate; and(i) isolating Factor VIII therefrom.